Silke Gillessen, MD, Author at Grand Rounds in Urology

Silke Gillessen, MD

Professor Silke Gillessen is a Medical Oncologist with focus on genitourinary cancer.

She completed her training in Basel, St. Gallen, and the Dana Farber Cancer Institute, Boston. After returning to Switzerland, she built up the medical oncology unit for genitourinary cancer and headed the clinical research unit for oncology/haematology in Cantonal Hospital, St Gallen.

She served for two terms as president of the SAKK GU group, she chaired the EORTC Genitourinary Cancers Group, and has founded the Advanced Prostate Cancer Consensus Conference (APCCC).

Since 2018, Prof. Gillessen has been Genitourinary Cancer Systemic Therapy Research Chair at the University of Manchester and Honorary Consultant at The Christie Hospital, while continuing to work as Consultant in the Department of Oncology/Haematology at the Kantonsspital St. Gallen, Switzerland.

In January 2020 Prof. Gillessen was appointed Head of the Department of Medical Oncology, full professor at the Università della Svizzera Italiana (USI) in Lugano and Director of the Oncology Institute of Southern Switzerland (IOSI) in Bellinzona, Switzerland.

Disclosures:

Talks by Silke Gillessen, MD

International, Multi-Disciplinary Consensus on Treatment of Advanced Prostate Cancer

Posted by Silke Gillessen, MD | Jun 2024

Silke Gillessen, MD analyzes the international, multi-disciplinary consensus on the treatment of advanced prostate cancer, emphasizing the collaborative efforts of experts from various medical fields. She highlights the critical importance of integrating diverse perspectives to develop effective treatment protocols.

The consensus process involves an extensive review of clinical data, expert opinions, and patient outcomes, ensuring that the recommendations are evidence-based and practical. Dr. Gillessen discusses key areas of agreement for treatment, including hormone therapy, chemotherapy, and novel targeted therapies.

Dr. Gillessen highlights the potential of new treatment modalities, such as PARP inhibitors and immunotherapies. Moreover, she advocates for treatment plans tailored to individual patient profiles, taking into account genetic, molecular, and clinical factors. This approach aims to enhance treatment efficacy and minimize adverse effects, aligning with the principles of precision oncology.

Silke Gillessen, MD

Talks by Silke Gillessen, MD

International, Multi-Disciplinary Consensus on Treatment of Advanced Prostate Cancer

Join the GRU Community

You have Successfully Subscribed!